Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company, and its corporate parent, Shin Nippon Biomedical ...

for the acute treatment of migraine with or without aura as a complete response to their January 2024 action letter. The Prescription Drug User Fee Act (PDUFA) date is set as April 30, 2025.

investigational therapeutic product for the acute treatment of migraine. STS101 is a unique and proprietary nasal powder formulation of the well-established anti-migraine drug, dihydroergotamine ...

(SNBL), is a late-stage biopharmaceutical company that is currently seeking regulatory approval from the U.S. Food and Drug Administration for STS101, a novel, investigational therapeutic product for ...

Nerivio is evidence-based treatment that, according to a study funded by manufacturer Theranica, significantly reduced ...

STS101 is an investigational DHE nasal powder product administered through a proprietary nasal delivery device.

These dots are often similar to "snow" or "static," like you'd see on an old television. It is usually black and white but can also appear as flashing, colored, or even transparent. For years, visual ...

Migraine treatment may be classified as prophylactic ... Headache with the features of migraine without aura usually follows the aura symptoms. Less commonly, headache lacks migrainous features ...

The U.S. Food and Drug Administration has expanded the age indication for Theranica's Nerivio, making it the first and only remote electrical neuromodulation (REN) wearable for migraine treatment ...

Analyst Douglas Tsao of H.C. Wainwright reiterated a Buy rating on Biohaven Ltd. (BHVN – Research Report), retaining the price target of ...